OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Headache
- Focus Therapeutic Use
- 24 Oct 2016 Status changed from recruiting to discontinued.
- 28 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016, according to ClinicalTrials.gov record.
- 28 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Sep 2016, according to ClinicalTrials.gov record.